
CLAIMS

1. Use of a compound of formula (**1**)



(**1**),

or a pharmaceutically acceptable salt thereof,

in the manufacture of a pharmaceutical composition for treating a central nervous system cancer in a subject in need thereof, wherein the central nervous system cancer has Dopamine Receptor D2 (DRD2) overexpression.

2. The use according to claim 1, wherein the cancer is meningioma, ependymoma, glioma, neuroblastoma or diffuse intrinsic pontine glioma.

3. The use according to claim 1 or 2, wherein the compound is an antagonist of the Dopamine Receptor D2 (DRD2).

4. The use according to any one of claims 1 to 3, wherein the subject is a human.

5. The use according to any one of claims 1 to 4, wherein the pharmaceutically acceptable salt is a di-hydrochloride salt.